This site is intended for health professionals only
Wednesday 12 December 2018
Share |

Topic: Other conferences & symposia

December 13, 2017
Results from the pooled analysis presented at the American Epilepsy Society Annual Meeting 2017 in Washington DC, USA

Bial and Eisai have announced new real-world audit data presented at the American Epilepsy Society (AES) Annual Meeting 2017, which add to the existing clinical trials examining the effectiveness and tolerability of Zebinix® (eslicarbazepine acetate).

 

May 24, 2016
More than 20,000 delegates attended the 50th Midyear Clinical Meeting of ASHP in New Orleans. Key topics included medication safety outside the pharmacy, virtual cleanrooms and miniaturised, on-demand drug manufacture

More than 20,000 delegates attended the 50th Midyear Clinical Meeting of ASHP in New Orleans. Key topics included medication safety outside the pharmacy, virtual cleanrooms and miniaturised, on-demand drug manufacture

 

 

January 25, 2016
First Phase III Vectibix trial to include a prespecified analysis of efficacy endpoints by RAS tumour status in primary analysis. Results presented at Gastrointestinal Cancers Symposium 2016 reinforce importance of RAS testing

January 11, 2016
In a study of 397 patients with ulcerative colitis and Crohn’s disease, 93 patients (23%) were switched to a biosimilar infliximab from the reference infliximab, representing the largest group of switch patients studied to date in inflammatory bowel diseases
  • In a study of 397 patients with ulcerative colitis and Crohn’s disease, 93 patients (23%) were switched to a biosimilar infliximab from the reference infliximab, representing the largest group of switch patients studied to date in inflammatory bowel diseases (IBD)1
     
November 19, 2015
Investigational HCV regimen with ABT-493 and ABT-530 evaluating a pan-genotypic, once-daily treatment option with shorter duration of therapy
September 22, 2015
FIP produces Arabic pictograms to help refugees with their medicines

The global refugee crisis, particularly the nine million Syrians estimated to have fled their homes since 2011, has prompted the International Pharmaceutical Federation (FIP) to undertake urgent work to help pharmacists ensure that refugees who need medicines understand how to take them. An Arabic version of the FIP pictogram software has been released. FIP’s pictograms provide a means of communicating medication instructions when there is no common language or when patients have low literacy levels.
 

 

August 18, 2015
Results from B-YOND study reinforce long-term clinical profile of Alprolix for the treatment of haemophilia B

Swedish Orphan Biovitrum AB (Sobi) and its partner Biogen released interim results from the B-YOND study presented at the 67th Annual Meeting for the National Hemophilia Foundation in Dallas, Texas. The results support the long-term safety and efficacy of Alprolix(R) (rFIXFc) in people with severe haemophilia B treated for up to two years. Participants in this Phase III, open-label long-term study maintained low bleeding rates with one to two week prophylaxis regimens. No inhibitors have been reported to-date.

 

June 16, 2015
New analyses from the EINSTEIN Clinical Trial Programme provide further data regarding the positive benefit–risk profile of Xarelto in specific patient populations. (1) Observational data from independent study in the UK provide real life insights into the risk of VTE in patients with active cancer. (1)

New analyses from the EINSTEIN Clinical Trial Programme provide further data regarding the positive benefit-risk profile of Xarelto in specific patient populations. (1) Observational data from independent study in the UK provide real life insights into the risk of VTE in patients with active cancer. (1)

 

June 8, 2015
New IntroDia™ Survey patient data was presented at American Diabetes Association’s® (ADA) 75th Scientific Sessions. IntroDia™ is an initiative of Boehringer Ingelheim and Lilly in partnership with the International Diabetes Federation.

New IntroDia™ Survey patient data was presented at American Diabetes Association’s®  (ADA) 75th Scientific Sessions. IntroDia™ is an initiative of Boehringer Ingelheim and Lilly in partnership with the International Diabetes Federation.

May 28, 2015
20,000 participants gathered in Anaheim, California for the 49th ASHP Midyear Clinical Meeting. Key topics included the biology of nitric oxide, Ebola virus management, medication errors with insulin and pharmacy practice issues

 

May 18, 2015
In conjunction with the opening of the 68th World Health Assembly, the International Federation of Psoriasis Associations, IFPA, launches an issue brief on psoriatic arthritis, calling the international community to action.

In conjunction with the opening of the 68th World Health Assembly, the International Federation of Psoriasis Associations, IFPA, launches an issue brief on psoriatic arthritis, calling the international community to action.

May 5, 2015
Bayer HealthCare reports that real-world data from a UK wide National Aflibercept Audit and Moorfields Aflibercept Audit have been presented at The Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting showcasing the efficacy of EYLEA® (aflibercept solution for injection) for the treatment of wet age-related macular degeneration (wAMD). The results from both audits highlight that treatment with aflibercept in NHS clinical practice has resulted in stabilised or improved visual and/or anatomical outcomes in treatment-naïve and pre-treated patients; (1–4) reflecting the results seen in the pivotal VIEW clinical trials. (5)
March 10, 2015
Amgen and its subsidiary Onyx Pharmaceuticals, Inc., announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) of Kyprolis® (carfilzomib) for injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The MAA has been granted accelerated assessment by the EMA.

Amgen and its subsidiary Onyx Pharmaceuticals, Inc., announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) of Kyprolis® (carfilzomib) for injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The MAA has been granted accelerated assessment by the EMA.
 

February 25, 2015
Researchers from the Medical Research Council Clinical Trials Unit (MRC CTU) and Public Health England have presented results at a conference in Seattle, Washington, indicating that pre-exposure prophylaxis (PrEP) is highly protective against HIV for gay and other men who have sex with men in England.

Researchers from the Medical Research Council Clinical Trials Unit (MRC CTU) and Public Health England have presented results at a conference in Seattle, Washington, indicating that pre-exposure prophylaxis (PrEP) is highly protective against HIV for gay and other men who have sex with men in England.

 

December 10, 2014
Takeda UK announced 4-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin) pivotal Phase II clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic ALCL, a type of T-cell lymphoma.

Takeda UK announced 4-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin) pivotal Phase II clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic ALCL, a type of T-cell lymphoma.

 

September 8, 2014
New data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014) show that overall treatment costs for cancer patients with clostridium difficile infection (CDI), based on a decision tree analysis, are lower with fidaxomicin compared to current standard of care, vancomycin, resulting in a potential cost saving of €5,600 per patient. (2)

New data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014) show that overall treatment costs for cancer patients with clostridium difficile infection (CDI), based on a decision tree analysis, are lower with fidaxomicin compared to current standard of care, vancomycin, resulting in a potential cost saving of €5,600 per patient. (2)  

September 4, 2014
New data from the international FIELD Study Repeat presented at the 15th World Congress of Cancers of the Skin (WCCS) in Edinburgh, Scotland, demonstrate initial treatment with Picato® (ingenol mebutate gel) 0.015% is efficacious in treating actinic keratoses (AK) and, when followed by a repeat cycle for persistent and newly emerging AKs, this efficacy is further increased. (1)

New data from the international FIELD Study Repeat presented at the 15th World Congress of Cancers of the Skin (WCCS) in Edinburgh, Scotland, demonstrate initial treatment with Picato® (ingenol mebutate gel) 0.015% is efficacious in treating actinic keratoses (AK) and, when followed by a repeat cycle for persistent and newly emerging AKs, this efficacy is further increased. (1)

September 3, 2014
Poor knowledge about antibiotics is not only a problem among uneducated sectors of society, according to the results of a survey of 731 students at Xi'an Jiaotong University, Shaanxi Province, China, presented at the World Congress of Pharmacy and Pharmaceutical Sciences.

Poor knowledge about antibiotics is not only a problem among uneducated sectors of society, according to the results of a survey of 731 students at Xi'an Jiaotong University, Shaanxi Province, China, presented at the World Congress of Pharmacy and Pharmaceutical Sciences.
 

July 17, 2014
The Congress of the International Society of Paediatric Oncology (SIOP 2014) will bring together worldwide experts in paediatric oncology. Learn from our top-notch faculty in symposia, lectures and in special sessions for each of our different programmes.

The Congress of the International Society of Paediatric Oncology (SIOP 2014) will bring together worldwide experts in paediatric oncology. Learn from our top-notch faculty in symposia, lectures and in special sessions for each of our different programmes.

The SIOP 2014 faculty includes: Professor Stephen Hunger, USA Representative Hematology Oncology, SIOP Scientific Committee and Rachel Hollis, UK Representative Nursing Group, SIOP Scientific Committee.

January 15, 2014
We are delighted to announce that the 46th Congress of the International Society of Paediatric Oncology (SIOP 2014) will take place October 22-25, 2014 in Toronto, Canada.

 

July 10, 2013
Patient Safety in Practice - HOPE-NVZ/NFU conference

Patient Safety in Practice - HOPE-NVZ/NFU conferenceFrom 10 to 12 June 2013, HOPE held its Agora in The Hague, the Netherlands, concluding the 32nd HOPE Exchange Programme.

June 12, 2013
SIOP 2013 is the largest annual paediatric cancer meeting in the world, attracting a multi-stakeholder attendance. This year's congress brings you a stimulating and diverse scientific programme

teaser

May 17, 2013
Bayer HealthCare has announced that new data on the oncology portfolio, including Nexavar

teaser

April 10, 2013
Orion will publish its Interim Report January-March 2013 on Tuesday, 23 April 2013 approximately at 12:00 Finnish time (EEST).

teaser

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine